Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Goodwill & Intangibles: 2010-2024

Historic Goodwill & Intangibles for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Dec 2024 value amounting to $57.2 million.

  • Lineage Cell Therapeutics' Goodwill & Intangibles fell 44.84% to $42.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.4 million, marking a year-over-year decrease of 44.84%. This contributed to the annual value of $57.2 million for FY2024, which is 0.04% down from last year.
  • According to the latest figures from FY2024, Lineage Cell Therapeutics' Goodwill & Intangibles is $57.2 million, which was down 0.04% from $57.2 million recorded in FY2023.
  • Over the past 5 years, Lineage Cell Therapeutics' Goodwill & Intangibles peaked at $76.8 million during FY2020, and registered a low of $57.2 million during FY2024.
  • Its 3-year average for Goodwill & Intangibles is $63.8 million, with a median of $57.2 million in 2023.
  • Data for Lineage Cell Therapeutics' Goodwill & Intangibles shows a maximum YoY declined of 25.49% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Goodwill & Intangibles stood at $76.8 million in 2020, then remained steady at $76.8 million in 2021, then remained steady at $76.8 million in 2022, then dropped by 25.49% to $57.2 million in 2023, then declined by 0.04% to $57.2 million in 2024.